NucleoTech, founded in 2022, is dedicated to enable better, noninvasive therapeutic solutions to CNS disorders. Through its innovative screening method, NucleoTech develops a set of proprietary carrier molecules that can effectively shuttle various therapeutics across the Blood-Brain Barrier, thus overcoming one of the main hurdles for effective, noninvasive CNS treatments.
Uriah Bekenstein, PhD, Co-Founder & CEO
Adi Koplovitz, Co-Founder & COO
Naftali Cohen, Co-Founder & head of Business
Tehila Dahan, PhD, R&D Manager
Beata Toth-Cohen, PhD, Research Adviser